Ovarian Cancer Pipeline & Market Canvassed in Topical GBI Research Report Now Available at MarketPublishers.com12 Jan 2016 • by Natalie Aster
LONDON – Ovarian cancer is the 6th most common cancer among women; it also causes more deaths than any other gynecological cancer. The 5-year survival rate is close to 45%, though this disease in most patients has a fatal outcome owing to a high recurrence rate. Surgery is typically deemed to be an effective therapy for patients with localised tumours, however the management of recurrent and later-stage disease largely rely upon anti-cancer (cytotoxic) chemotherapy regimens.
There are favourable signs in the pipeline that the industry is looking for novel approaches the treating ovarian cancer. Ovarian cancer treatment has an extremely active pipeline containing a host of versatile molecular targets and molecule types, contrary to the marketplace. With the diversity in the pipeline, innovative products will likely be able to make it to market to equip patients with more diverse therapeutic options, whilst responding to unmet needs within the ovarian cancer market. Currently, there are 179 ovarian cancer pipeline products with respect to a first-in-class molecular target, representing 52% of all pancreatic cancer pipeline products with a disclosed molecular target. Such a versatile and innovative pipeline signifies that approaches to the treatment pf the disease are undergoing changes, with first-in-class development playing a considerable part in this.
Topical research report “Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation” elaborated by GBI Research provides an in-depth understanding of the present-day clinical and commercial landscape, including a detailed review of ovarian cancer pathogenesis, diagnosis, prognosis and the current treatment moodalities available at each stage of diagnosis. The study gives an analysis of the ovarian cancer market with respect to key molecule targets and types, limelighting what the present-day unfilled needs are and how they can be responded to, which allows a refined understanding of gaps in today’s market. The report provides an analysis of the ovarian cancer pipeline, categorising it by development stage, type of molecule as well as molecular target. It assessed and ranks first-in-class targets according to clinical potential, with promising early-stage targets being further surveyed in more detail. The study identifies commercial opportunities in the ovarian cancer deals landscape by evaluating trends in co-development and licensing deals and delivering a curated list of ovarian cancer treatment modalities that may be investment opportunities in the offing.
Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation
Published: December, 2015
Price: US$ 6,995.00
More studies by the publisher can be found at GBI Research page.